AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF) comprising:

a therapeutically effective amount of a non-glycosylated G-CSF in a concentration ranging from about 0.3 mg/ml to about 0.96 mg/ml, and

an acid. wherein the composition is free of any surfactant, the composition is an aqueous liquid, and the composition has a pH value ranging from about 4.2 to about 4.8

wherein the amount of G-CSF higher aggregates in the composition after storage for 1 month at 40 degrees C is no more than about 0.65% of the amount of G-CSF in the composition.

Claim 2. (Original) The composition of claim 1, wherein the pH of the composition is at about 4.4.

Claim 3. (Previously Presented) The composition according to claim 1 further comprising:

a. a pH buffering system and/or

b. one or more pharmaceutically acceptable excipient(s).

Claims 4.-5. (Cancelled)

Claim 6. (Original) The composition of claim 1, wherein the acid is selected from the group consisting of acetic acid, HCl. maleic acid, glutamic acid, methansulphonic acid, citric acid, malonic acid, lactic acid, sulphuric acid, and phosphoric acid.

Claim 7. (Original) The composition of claim 6, wherein the acid is selected from the group consisting of acetic acid and HCl.

Claim 8. (Previously Presented) The composition of claim 1 further comprising a polyol is selected from the group consisting of sorbitol, glycerol. inositol and mannitol.

Claim 9. (Previously Presented) The composition of claim 8, wherein the polyol is sorbitol.

Claim 10. (Previously Presented) The composition of claim 9, wherein sorbitol is present in an amount from about 1 % to about 10%.

Claim 11. (Previously Presented) The composition of claim 9, wherein sorbitol is present in an amount from about 3% to about 8%.

Claim 12. (Previously Presented) The composition of claim 3 wherein the pH buffering system is selected from the group consisting of acetic acid/acetate and phosphoric acid/phosphate.

Claim 13. (Previously Presented) The composition of claim 12, wherein the pH buffering system is acetic acid/acetate.

Claim 14. (Previously Presented) The composition of claim 13, wherein the concentration of acetic acid is in the range from about 0.15 mM to about 15 mM.

Claim 15. (Previously Presented) The composition of claim 14 wherein the concentration of acetic acid is in a range from about 1.5 mM to about 10 mM.

Claims 16-18. (Cancelled)

Claim 19. (Previously Presented) The composition of claim 1, wherein the pH of the composition is at about 4.2.

Claim 20. (Currently Amended) A stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF) comprising:

a therapeutically effective amount of a non-glycosylated G-CSF having a concentration ranging from about 0.3 mg/ml to about 0.96 mg/ml,

a polyhydric alcohol selected from the group consisting of sorbitol, glycerol, inositol, mannitol, and mixtures thereof, and

an acid, wherein the composition is free of a surfactant, the composition is an aqueous liquid, and the composition has a pH value ranging from about 4.2 to about 4.8

wherein the amount of G-CSF higher aggregates in the composition after storage for 1 month at 40 degrees C is no more than about 0.65% of the amount of G-CSF in the composition.

Claim 21. (Currently Amended) A stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF) comprising a therapeutically effective amount of a non-glycosylated G-CSF and an acid, wherein the acid is the sole excipient, and wherein the composition has a pH value ranging from about 4.2 to about 4.8

wherein the amount of G-CSF higher aggregates in the composition after storage for 1 month at 40 degrees C is no more than about 0.65% of the amount of G-CSF in the composition.

Claim 22. (New) The stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF) of Claim 1, wherein the amount of G-CSF higher aggregates in the composition after storage for 1 month at 40 degrees C is no more than about 0.13 % of the amount of G-CSF in the composition.

Claim 23. (New) The stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF) of Claim 20. wherein the amount of G-CSF higher aggregates in the composition after storage for 1 month at 40 degrees C is no more than about 0.13 % of the amount of G-CSF in the composition.

Claim 24. (New) The stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF) of Claim 21. wherein the amount of G-CSF higher aggregates in the composition after storage for 1 month at 40 degrees C is no more than about 0.13 % of the amount of G-CSF in the composition.